Skip to main content

Table 1 Characteristics of patients at ICU admission

From: The use of ICU resources in CAR-T cell recipients: a hospital-wide study

N (%) or Median [IQR] Overall (n = 71)
Demographics
 Age 60 [37–67.5]
 Male gender 42 (59%)
Comorbidities  
 Hypertension 10 (14%)
 Diabetes 3 (4%)
 Chronic kidney disease 2 (3%)
 Body mass index (kg/m2) 24 [22–26]
ECOG Performance status
 Median PS 1 [1–2]
 PS 0 11 (15.5%)
 PS 1 32 (45%)
 PS 2 22 (31%)
 PS 3 6 (8.5%)
Hematological malignancy
 Diffuse large B cell lymphoma 53 (75%)
 Lymphoblastic leukemia 17 (24%)
 Multiple myeloma 1 (1%)
 Time between hematological diagnosis and ICU admission (months) 12 [10–16]
Previous hematological treatments
 Number of treatment lines prior to CAR-T cells 3 [3–4]
 Autologous stem cell transplantation 10
 Bone marrow transplantation 5
 Blinatumomab 11
CAR-T cell therapy
 Autologous CAR-T cells 69
 Axicabtagene ciloleucel 33 (46%)
 Tisagenlecleucel 31 (44%)
 Brexucabtagene autoleucel 4 (5.5%)
 bb2121 1 (1.5%)
 Allogeneic CAR-T cells (UCART19) 2 (3%)
 Time between CAR-T cell infusion and ICU admission (days) 6 [4–7]
Clinical and biological features at ICU admission
 Mean arterial blood pressure (mmHg) 68 [60–81]
 Temperature (°C) 39.5 [38.5–40]
 Neutropenia 47 (66%)
 SOFA score 4 [2–6]
  1. ICU intensive care unit, PS Performance status, SOFA Sepsis-related Organ Failure Assessment